Drug-induced hepatotoxicity is a major safety concern in clinical therapy, because nearly 50% of oral drugs on the market are associated with hepatotoxicity.3 Unfortunately, BCR-ABL TKIs are no exception.4 To date, more than 25 clinical cases of the first generation BCR-ABL TKI imatinib-induced hepatitis have been reported.5,6 As for the new-generation BCR-ABL TKIs, ponatinib therapy can cause rare instances of clinically apparent liver disease and even death,7,8,9 prompting the FDA to issue a boxed warning. This evidence concerns the gene ABL1 and hepatitis A virus infection.